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Abstract
Objective—Neuropsychiatric (NP) events occur unpredictably in systemic lupus erythematosus 
(SLE) and most biomarker associations remain to be prospectively validated. We examined a 
disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrollment 
predicted subsequent NP events.
Methods—Patients with recent SLE diagnosis were assessed prospectively for up to 10 years for 
NP events using ACR case definitions. Decision rules of graded stringency determined whether 
NP events were attributable to SLE. Associations between the first NP event and baseline 
autoantibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein-I, anti-ribosomal P and 
anti-NR2 glutamate receptor) were tested by Cox proportional hazards regression.
Results—Disease duration at enrollment was 5.4±4.2 months, followup was 3.6±2.6 years. 
Patients were 89.1% female with mean (±SD) age 35.2±13.7 years. 495/1047 (47.3%) developed 
≥1 NP event (total 917 events). NP events attributed to SLE were 15.4% (model A) and 28.2% 
(model B). At enrollment 21.9% of patients had lupus anticoagulant, 13.4% anticardiolipin, 15.1% 
anti-β2 glycoprotein-I, 9.2% anti-ribosomal P and 13.7% anti-NR2 antibodies. Lupus 
anticoagulant at baseline was associated with subsequent intracranial thrombosis (total n=22) 
attributed to SLE (model B) (Hazard ratio, HR 2.54 (95% CI: 1.08–5.94). Anti-ribosomal P 
antibody was associated with subsequent psychosis (total n=14) attributed to SLE (model B) (HR: 
3.92 (95% CI:1.23–12.5); p=0.02). Other autoantibodies did not predict NP events.
Conclusion—In a prospective study of 1047 recently diagnosed SLE patients, lupus 
anticoagulant and anti-ribosomal P antibodies are associated with an increased future risk for 
intracranial thrombosis and lupus psychosis respectively
Keywords
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Nervous system involvement in systemic lupus erythematosus (SLE) encompasses a variety 
of neurological (N) and psychiatric (P) features. Using the American College of 
Rheumatology (ACR) case definitions (1), the prevalence of neuropsychiatric (NP) disease 
in SLE varies from 21–95%, but only 19–38% of eventsare a ttributable to lupus (2–6). NP 
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events present or reoccur at any time in the disease course, although the majority occurs 
around the time of diagnosis of SLE, particularly those attributable to SLE (7–11). The 
identification of biomarkers at the time of diagnosis to quantify the subsequent risk of NP 
events attributable toSLE (NPSLE) would be helpful.
NPSLE is likely mediated by autoantibodies, microvasculopathy, and the intracranial 
production of inflammatory mediators (12–15), ofter in combination. Lupus related 
autoantibodies most frequently associated with NPSLE include antiphospholipid antibodies, 
anti-ribosomal P antibodies and autoantibodies which bind to neuronal antigens such as the 
N-methyl-D-aspartate (NMDA) glutamate receptor (anti-NR2) (16). Although there is 
biological plausibility and experimental data (16–20) to implicate these autoantibodies in the 
causality of nervous system disease, studies of human SLE have provided inconsistent 
findings (21–25). Limitations of previous studies include their cross-sectional design, 
inclusion of patients with variable disease duration, and lack of standardization in both the 
classification of NP events and the methodology used for autoantibody detection. We have 
assembled an international, inception cohort of SLE patients to examine the association 
between a panel of autoantibodies measured within a mean of 6 months of the time of 
diagnosis and subsequent nervous system events over a mean followup of 3.6 years. 
Attribution models of different stringency were used to distinguish NP events attributed to 
SLE and non-SLE causes.
Patients and Methods
Research study network
The study was conducted by members of the Systemic Lupus International Collaborating 
Clinics (SLICC) (26) a network of 37 investigators in 30 international academic medical 
centres in 11 countries. Twenty-one centres participated in the study. Data were collected 
prospectively on patients presenting with a new diagnosis of SLE. All information was 
submitted to the coordinating centre in Halifax, Nova Scotia, Canada and entered into a 
centralized Access database. Appropriate procedures ensured data quality, management and 
security. The studyl was approved by the Capital Health Research Ethics Board, Halifax, 
Nova Scotia, Canada and by each of the participating centre’s own institutional research 
ethics review boards.
Patients
Patients fulfilled the ACR classification criteria for SLE (27) provided written informed 
consent. The date of diagnosis was when these cumulative criteria were first recognized. 
Enrollment was permitted up to 15 months following the diagnosis. Variables collected 
included age, gender, ethnicity, education and medication history. Lupus-related variables 
included the ACR classification criteria for SLE (27), the SLE Disease Activity Index 
(SLEDAI) (28) and the SLICC/ACR damage index (SDI) (29). Laboratory variables were 
hematology, serum and urine chemistry and immunologic variables (including anti-DNA 
antibodies) required for the generation of SLEDAI and SDI scores.
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An enrollment window within which all NP events were captured extended from 6 months 
prior to the diagnosis of SLE up to the enrollment date. NP events were characterized using 
the ACR nomenclature and case definitions for 19 NP syndromes (1). These were diagnosed 
by clinical evaluation and investigations were performed if clinically warranted.
Patients were reviewed annually with a 6-month window around the anticipated assessment 
date. New NP events since the previous study visit and their attribution were determined.
Supplementary information was recorded as per the ACR glossary for NP syndromes (1) to 
identify other potential causes (“exclusions”) or contributing factors (“associations”) for 
each of the NP events. These “non-SLE factors” were used in part to determine the 
attribution of NP events. Patients could have more than one type of NP event and repeated 
episodes of the same event within the enrollment window or within a follow-up assessment 
period were recorded once. The date of the first episode was taken as the onset of the NP 
event within the particular time frame.
Attribution of NP events
Decision rules were used to determine the attribution of all NP events. Factors considered in 
the decision rules included: (i) onset of NP event(s) prior to the diagnosis of SLE; (ii) 
concurrent non-SLE factor(s) identified from the ACR glossary for each NP syndrome and 
(iii); “common” NP events which are frequent in normal population controls as described by 
Ainiala et al (30). These include all headaches, anxiety, mild depression (mood disorders 
failing to meet criteria for “major depressive-like episodes”), mild cognitive impairment 
(deficits in less than 3 of the 8 specified cognitive domains) and polyneuropathy without 
electrophysiological confirmation.
Attribution of NP events was determined by the central application of decision rules of 
different stringency (models A and B) as described in detail elsewhere (31, 32). NP events 
which fulfilled the criteria for model A (the most stringent) or for model B (the least 
stringent) were attributed to SLE. By definition, all NP events attributed to SLE using model 
A were included in the group of NP events attributed to SLE using model B. Those events 
which did not fulfill these criteria were attributed to non-SLE causes
Determination of autoantibodies
Autoantibodies were measured in Dr. Joan Merrill’s laboratory at the Oklahoma Medical 
Research Foundation, USA. Autoantibody determinations were made without knowledge of 
the occurrence of NP events or their attribution in individual patients.
ELISA for anti-NR2 antibodies—NR2 human peptide sequence, (Asp Trp Glu Tyr Ser 
Val Trp Leu Ser Asn)8 Lys 4 Lys2 Lys-β Ala, was synthesized using f-moc chemistry, 
purified by HPLC and confirmed by Edman degradation at the Molecular Biology 
Proteomics Facility of the University of Oklahoma Health Sciences Centre, Oklahoma City, 
OK. High binding, Nunc 96-well polystyrene plates were coated with 5 ug/mL of NR2 
peptide in borate buffered saline and blocked with borate buffered saline, bovine serum 
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albumin (Fraction V, Sigma) and 1.2% Tween 80. Patient sera, positive and negative controls 
were added, diluted 1/100 in the same blocking buffer. Plates were washed with borate 
buffered saline between each step with vigorous pounding to eliminate non-specific binding. 
Secondary antibody was an alkaline phosphatase conjugated goat anti-human IgG (Sigma) 
with the addition of goat serum to block non-specific binding (donor herd, Sigma). Plates 
were developed using p-NPP substrate buffer (Sigma). Optical density of the enzyme-linked 
immune assay were read at 405 (primary wavelength) and 450 (secondary wavelength). 
Serial dilutions of a high binding positive control were used as a calibrator.
Antiphosphilipid, anti-β2 glycoprotein-I, and anti-ribosomal P antibodies—
Lupus anticoagulant (LA) and ELISAs for anticardiolipin, anti-β2 glycoprotein-I and anti-
ribosomal P protein were performed as previously described (33–35). The LA assay was 
performed using screen and confirm reagents from Rainbow Scientific, 83 Maple Ave., 
Windsor, CT. Each reagent was standardized against20 plasmasamples (collected in citrate) 
from healthy donors. A normal reference range was derived from calculating two standard 
deviations above the mean of healthy controls on the screen and confirm (phospholipid 
quenched) tests and calculating the ratio of screen value/confirm value. Patient’s clotting 
time for LA Screen was divided by the LA Confirm’s clotting time. If this number was 
above the normal reference range, the patient was considered positive for LA. β2 
glycoprotein-I, purified from human plasma, was the gift of Drs. Naomi and Charles Esmon, 
and ribosomal P protein was provided by Dr. Morris Reichlin, Oklahoma Medical Research 
Foundation. Each ELISA was validated against a curve, constructed using serial dilutions of 
a high binding serum. In the case of anticardiolipin and anti-ribosomal P protein, these 
calibrators were previously established in Dr. Reichlin’s laboratory. In the case of anti-β2 
glycoprotein-I the calibrator was established by the Registry for the Antiphospholipid 
Syndrome at Oklahoma. The cutoff for positive was defined as 2 SD above the mean of 60 
healthy controls and/or position on the flat part of the calibrator curve, whichever was 
associated with the higher O.D. On each ELISA plate, positive and negative control sera 
(established previously from the laboratory collection and frozen at −80°C in assay specific 
aliquots) were run to ensure a valid assay.
Statistical analysis
Chi-square tests were used to examine the association of autoantibody prevalence at 
enrollment with geographical regions or ethnic/racial groups. The associations of 
autoantibodies at enrollment with the time to the first occurrence of NP events overall, or 
events attributed to SLE (model A or model B) as well as the time to the first occurrence of 




A total of 1047 patients were recruited between October 1999 and April 2010. The median 
(range) number of patients enrolled in each of the 21 centres was 31 (6–161). The patients 
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were predominantly women, with a mean (±SD) age of 35.2±13.7 years and a wide ethnic 
distribution although predominantly Caucasian (Table 1).
At enrollment the mean disease duration was only 5.4±4.2 months despite the opportunity to 
recruit patients up to 15 months following the diagnosis of SLE. The prevalence of 
individual ACR classification criteria at enrollment reflected an unselected patient 
population. The mean SLEDAI and SDI scores revealed moderate global disease activity and 
minimal cumulative organ damage respectively. Therapy at enrollment reflected the typical 
range of lupus medications. The number of assessments in individual patients varied from 1 
to 10 over a mean followup 3.6 ± 2.6 years.
Neuropsychiatric (NP) manifestations
495/1047(47.2%) patients had ≥1 NP event and 226/1047(21.5%) had ≥2 events. The events 
and their attribution are summarized in Table 2.
There were 917 NP events, encompassing 17 of the 19 NP syndromes: headache (52.0%), 
mood disorders (14.4%), seizure disorder (5.8%), anxiety disorder (5.7%), cerebrovascular 
disease (5.1%), cognitive dysfunction (4.5%), polyneuropathy (2.5%), acute confusional 
state (2.3%), mononeuropathy (1.7%), psychosis (1.7%), cranial neuropathy (1.2%), 
movement disorder (0.9%), myelopathy (0.9%), aseptic meningitis (0.7%), demyelinating 
syndrome (0.4%), autonomic neuropathy (0.1%) and plexopathy (0.1%). The proportion of 
NP events attributed to SLE varied from 15.4% – 28.2% using alternate attribution models 
and occurred in 9.7 % [model A] – 16.5 % [model B] of patients. There were no patients 
with Guillain-Barré syndrome or myasthenia gravis. Of the 917 NP events 865 (94.3%) 
affected the central nervous system and 52 (5.7%) involved the peripheral nervous system. 
The classification of events into diffuse and focal was 749 (81.7%) and 168 (18.3 %), 
respectively.
Autoantibodies and Racial/Ethnic Group
The prevalence of autoantibodies is illustrated in Figure 1. This varied from 9.2% (91/991) 
for anti-ribosomal P antibodies, 13.4% (133/995) for anticardiolipin, 13.7% (126/923) for 
anti-NR2, 15.1% (150/994) for anti-β2 glycoprotein-I and 21.9% (228/1042) for LA. The 
number of patients with 1, 2 or ≥3 positive antibody tests were 312, 107 and 61, respectively. 
The frequency of autoantibodies varied by geographical region. Specifically the frequency of 
LA was lower in Canadian centres (15.2%) compared to centres in the USA (26.0%), 
Europe (23.1%), Asia (22.6%) and Mexico (30.8%) (p=0.015), and the frequency of anti-
ribosomal P antibodies was higher in Mexico (29.0%) compared to Canada (7.3%), USA 
(7.5%), Europe (8.0%) and Asia (13.7%) (p<0.001). In large part these findingswere due to 
the associationof racial/ethnic group with autoantibody frequencies (Table 3).
Autoantibodies and overall NP events
There was no significant positive association between autoantibodies and first occurrence of 
NP events overall, or events attributed to SLE (model A or model B). Clustering of NP 
events into diffuse/focal and central/peripheral manifestations did not change the outcome of 
this analysis. In keeping with our previous findings (36) the presence of anti-DNA 
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antibodies measured at individual SLICC sites did not positively predict the occurrence of 
NP events (data not shown).
Autoantibodies and individual NP events
Analyses were also performed to examine specific a priori clinical-serologic associations. 
The association between antiphospholipid antibodies and cerebrovascular disease and 
between anti-ribosomal P antibodies and psychosiswere of particular interest (Table 4 and 
Figure 2).
Cerebrovascular disease includes stroke, transient ischemic attack, chronic multifocal 
disease, subarachnoid or intracranial hemorrhage and sinus thrombosis. There was no strong 
relationship demonstrated between cerebrovascular disease, so defined, and the presence of 
any one of either anti-β2 glycoprotein-I, anticardiolipin antibody or LA (Hazard ratio, HR 
1.26 (95% CI 0.69–2.30). However, LA at baseline and the occurrence of cerebrovascular 
disease approached statistical significance (HR 1.84 (95% CI) 0.92–3.68) and the 
association with stroke/sinus thrombosis (total n=22) attributed to SLE (model B) was 
statistically significant (HR 2.54 (95% CI 1.08–5.94). The median (range) between the 
detection of LA and first stroke/sinus thrombosis was 5.02 (0–7.36) years. In addition, anti-
ribosomal P antibody at baseline was associated with psychosis (total n=14) attributed to 
SLE (model B) (HR 3.92 (95% 1.23–12.5). Seven of the patients with psychosis were 
African, 5 Caucasian and 1 each Hispanic and Asian. Given the higher rate of psychosis in 
Africans (p<0.01), adjustment for racial/ethnic group (African/others) was undertaken. This 
led to a reduction in the hazard ratio for anti-ribosomal P antibody and subsequent psychosis 
to 3.1 with a corresponding shift in the confidence interval (0.95–9.99). The median (range) 
between the detection of anti-ribosomal P antibody and first episode of psychosis was 5.69 
(0–9.16) years.
Discussion
We have evaluated the usefulness of measuring selected autoantibodies for predicting the 
occurrence of NPSLE in a large, international, inception cohort of SLE patients over the first 
10 years of disease. Our findings provide some evidence that LA and anti-ribosomal P 
antibodies are significantly associated with specific manifestations of NP disease attributed 
to SLE, namely intracranial thrombosis and psychosis respectively. Variability in the 
frequency of some autoantibodies with racial/ethnic group supports previous observations of 
this kind (36, 37) and likely alters the risk profile for the occurrence of NP events in some 
groups of patients.
There several strengths to our study. In contrast to previous retrospective and cross-sectional 
clinical studies of NPSLE, ours was prospective to identify the characteristics and attribution 
of all NP events using a predefined annual data collection protocol. The multi-centre, 
international, longitudinal study design provides a basis for extrapolating our findings to the 
broader community of SLE patients. Although nervous system involvement by SLE has long 
been recognized, the lack of specificity of multiple individual manifestations and difficulty 
in identifying the correct attribution of the clinical NP events has been challenging. The 
ACR case definitions of 19 NP syndromes (1) which were developed over a decade ago have 
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provided a much needed and now widely used platform for the classification of NP events in 
SLE cohorts. We have also used the accompanying ACR glossary with other information to 
derive decision rules for determining attribution of NP events to SLE or non-SLE causes 
(32). In previous studies the application of these decision rules has demonstrated significant 
correlations with clinical outcomes and selected autoantibodies (31, 32, 38, 39). The use of 
these rules in the current study provides an excellent platform for the prospective evaluation 
of potential biomarkers of NPSLE.
The search for biomarkers of NPSLE is based upon what is already known of the 
pathogenesis of the disease. There is robust evidence from several sources to implicate a 
pathogenic role for autoantibodies, microvasculopathy, and the intracranial production of 
inflammatory mediators. These studies have provided a menu of biomarker candidates, 
including autoantibodies, cytokines and other inflammatory molecules (40) as well as 
soluble markers of neuronal and glial degradation (41). Detailed discussion is not possible 
here but a few general observations are worthy of comment. First, given the multitude of 
clinical manifestations it is very unlikely that a single biomarker will reliably predict all NP 
events. Second, the anatomical location of biomarkers is important in some cases. For 
example the association of diffuse NP events with autoantibodies is significantly stronger if 
these are measured in cerebrospinal fluid (CSF), whereas autoantibodies associated with 
focal NP events are best studied in peripheral blood. An alternative to accessing CSF, is to 
find a biomarker of increased permeability of the blood-brain-barrier, a critical factor if 
some autoantibodies are to reach their target antigen and cause clinical disease. Finally, it is 
possible that combinations of biomarkers reflecting different components of the pathogenic 
model of NPSLE will best predict clinical events. To our knowledge, there are no previous 
studies which have set out to evaluate biomarkers of NPSLE in a large multi-ethnic cohort of 
patients specifically recruited as close to the diagnosis of SLE as possible and followed over 
an extended period. Some but not all previous cross-sectional studies with smaller sample 
sizes have found an association between lupus anticoagulant and intracranial thrombosis 
(42) and between anti-ribosomal P antibodies and lupus psychosis (24, 43–47). However, in 
these studies the autoantibodies were measured in close temporal proximity to the clinical 
event. In contrast, our study is the first to demonstrate the risk of a single autoantibody 
determination around the time of diagnosis of SLE for a subsequent and often remote NP 
event.
There are several limitations to the current study. First, the number of autoantibodies studied 
was limited and CSF samples were not available. The selection of autoantibodies was based 
upon the evidence of their pathogenic role. Access to CSF samples in our study was 
infrequent and was restricted to situations when a lumbar puncture was clinically indicated. 
Also, the small number of specific NP events allowed little power for adjusted analyses. 
Second, as the study involved antibody determination at a single point in time, no 
information is yet available on the predictive value of sustained circulating levels of 
autoantibodies. Third, the classification of NP status was determined primarily by clinical 
assessment and using appropriate investigations only when clinically indicated. Specialized 
and sensitive investigations such as MRI neuroimaging studies and formal 
neuropsychological assessment of cognitive function were not routinely done on all patients. 
Their use would very likely have resulted in the recognition of additional structural and 
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function abnormalities of the nervous system. However, many of the abnormalities would be 
of dubious clinical significance and the routine use of such investigations, although justified 
in the context of a clinical study, would not mirror what is most commonly done in clinical 
practice. Finally, the duration of followup in the current study does not reflect the lifetime 
experience with NP events experienced by the majority of SLE patients. We and others have 
previously reported that NP events, especially those attributed to SLE, occur most frequently 
within the first 2 years of the diagnosis of SLE (7–11), thus emphasizing the importance of 
this period of observation. Nevertheless further followup is required to identify the longer 
term association between autoantibodies detected either at baseline or over the duration of a 
patients’ illness and clinical expression of NPSLE. The long-term objective of our 
prospective study is to follow all patients for 10 years which will provide an excellent 
platform to find new and stronger associations with circulating serological biomarkers.
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Frequency of autoantibodies at enrollment. (LA=lupus anticoagulant; aCL=IgG 
anticardiolipin antibody; Anti-β2-GPI=IgG anti-β2 glycoprotein I antibody; Anti -ribo 
P=IgG anti-ribosomal P antibody; Anti-NR2=IgG anti-NR2 glutamate receptor antibody)
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Kaplan-Meier time-to-event curves for intracranial thrombosis in patients with and without 
lupus anticoagulant (LA) (left panel) and for psychosis in patients with and without anti-
ribosomal P antibodies (Anti-P) (right panel).
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Table 1
Demographic and clinical manifestations of SLE patients at enrollment
Number of Patients 1047
Gender
 Female 933 (89.1%)
 Male 114 (10.9%)
Age (years) (mean ± SD) 35.2 ± 13.7
Race/Ethnicity:
 Caucasian 545 (52.1%)
 Asian 225 (21.5%)
 African 160 (15.3%)
 Hispanic 73 (7.0%)
 Other 44 (4.2%)
Single/Married/Other 481 (45.9%)/435 (41.6%)/131(12.5%)
Post secondary education 672 (66.9%) (range 36.4–100%)
Disease duration (months) (mean ± SD) 5.4 ± 4.2
Number of ACR criteria (mean ± SD) 4.9 ± 1.0
Cumulative ACR manifestations
 Malar rash 364 (34.8%)
 Discoid rash 118 (11.3%)
 Photosensitivity 368 (35.1 %)
 Oral/nasopharyngeal ulcers 391 (37.3%)
 Serositis 280 (26.7%)
 Arthritis 759 (72.5%)
 Renal disorder 278 (26.6%)
 Neurological disorder 57 (5.4%)
 Hematologic disorder 639 (61.0%)
 Immunologic disorder 807 (77.1%)
 Antinuclear antibody 1017 (97.1%)
SLEDAI score (mean ± SD) 5.5 ± 5.4
SLICC/ACR damage index score (mean ± SD) 0.24 ± 0.67
Medications
 Corticosteroids 718 (68.6%)
 Antimalarials 690 (65.9%)
 Immunosuppressants 402 (38.4%)
 ASA 144 (13.8%)
 Antidepressants 104 (9.9%)
 Warfarin 58 (5.5%)
 Anticonvulsants 37 (3.5%)
 Antipsychotics 6 (0.6%)
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Table 2
Characteristics of cumulative neuropsychiatric syndromes over the study period in SLE patients with ≥1 
autoantibody measurement at enrollment (n=1047). The number of NP events and their attribution are 
indicated using attribution models A and B
NP events (%)regardless of 
attribution
NP events due to SLE 
(model A)
NP events due to SLE 
(Model B)
NP events due to non-
SLE causes
Headache 477 (52.0) 0 0 477
Mood disorders 132 (14.4) 23 54 78
Seizure disorder 53 (5.8) 32 44 9
Anxiety disorder 52 (5.7) 0 0 52
Cerebrovascular disease 47 (5.1) 22 46 1
Cognitive dysfunction 41 (4.5) 10 28 13
Polyneuropathy 23 (2.5) 7 11 12
Acute confusional state 21 (2.3) 10 15 6
Mononeuropathy 16 (1.7) 6 16 0
Psychosis 16 (1.7) 9 16 0
Cranial neuropathy 11 (1.2) 8 8 3
Movement disorder 8 (0.9) 1 5 3
Myelopathy 8 (0.9) 4 7 1
Aseptic meningitis 6 (0.7) 4 4 2
Demyelinating syndrome 4 (0.4) 1 4 0
Autonomic disorder 1 (0.1) 1 1 0
Plexopathy 1 (0.1) 0 0 1
Guillain-Barre syndrome 0 0 0 0
Myasthenia gravis 0 0 0 0
Total 917 141 259 658
% among 917 NP events 15.4 28.2 71.8
*
The attribution of neuropsychiatric (NP) events to SLE was determined using two attribution models:
Attribution Model A: NP events which had their onset within the enrollment window and had no “exclusions” or “associations” and were 
not one of the NP events identified by Ainiala (30) were attributed to SLE.
Attribution Model B: NP events which had their onset within 10 years of the diagnosis of SLE and were still present within the enrollment 
window and had no “exclusions” and were not one of the NP events identified by Ainiala (30)were attributed to SLE.
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Table 4
The association between autoantibodies and the time to specific NP manifestations as indicated by hazard ratio 
(95% CI)
LA aCl Anti-β2-GPI Anti-β2-GPI or aCL or LA
Any cerebrovascular Event (model B) 1.84 (0.92–3.68) 1.25 (0.52–3.02) 1.14 (0.48–2.76) 1.26 (0.69–2.30)
Stroke or sinus thrombosis (model B) 2.54 (1.08–5.94) 0.65 (0.15–2.78) 0.27 (0.04–2.04) 1.25 (0.58–2.72)
Anti-ribosomal P
Psychosis (model B) 3.92 (1.23–12.50)
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